Kaur Alasoo

Kaur Alasoo

Auto-generated profile, based on publicly available information

Kaur Alasoo

Institute of Computer Science, University of Tartu, Tartu, Estonia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2017 in Nature
Verified
Journal Article
Open access
PDF file
HKHelena Kilpinen
Helena Kilpinen
AGAngela Goncalves
Angela Goncalves
ALAndreas Leha
Andreas Leha
VAVackar Afzal
Vackar Afzal
KAKaur Alasoo
Kaur Alasoo
DGDaniel J. Gaffney
Daniel J. Gaffney
Technology utilizing human induced pluripotent stem cells (iPS cells) has enormous potential to provide improved cellular models of human disease. However, variable genetic and phenotypic characterization of many existing iPS cell lines limits their potential use for research and therapy. Here we describe the systematic generation, genotyping and phenotyping of 711 iPS cell lines derived from 301 healthy individuals by the Human Induced Pluripotent Stem Cells Initiative. Our study outlines the major sources of genetic and phenotypic variation in iPS cells and establishes their suitability as models of complex human traits and cancer. Through genome-wide profiling we find that 5–46% of the variation in different iPS cell phenotypes, including differentiation capacity and cellular morphology, arises from differences between individuals. Additionally, we assess the phenotypic consequences of genomic copy-number alterations that are repeatedly observed in iPS cells. In addition, we present a comprehensive map of common regulatory variants affecting the transcriptome of human pluripotent cells.

6 September 2021 in Nature Genetics
Verified
Journal Article
Open access
PDF file
NKNurlan Kerimov
Nurlan Kerimov
JHJames D. Hayhurst
James D. Hayhurst
KPKateryna Peikova
Kateryna Peikova
JMJonathan R. Manning
Jonathan R. Manning
PWPeter Walter
Peter Walter
KAKaur Alasoo
Kaur Alasoo
Many gene expression quantitative trait locus (eQTL) studies have published their summary statistics, which can be used to gain insight into complex human traits by downstream analyses, such as fine mapping and co-localization. However, technical differences between these datasets are a barrier to their widespread use. Consequently, target genes for most genome-wide association study (GWAS) signals have still not been identified. In the present study, we present the eQTL Catalogue (https://www.ebi.ac.uk/eqtl), a resource of quality-controlled, uniformly re-computed gene expression and splicing QTLs from 21 studies. We find that, for matching cell types and tissues, the eQTL effect sizes are highly reproducible between studies. Although most QTLs were shared between most bulk tissues, we identified a greater diversity of cell-type-specific QTLs from purified cell types, a subset of which also manifested as new disease co-localizations. Our summary statistics are freely available to enable the systematic interpretation of human GWAS associations across many cell types and tissues.

29 January 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
HCHIPSCI Consortium
HIPSCI Consortium
KAKaur Alasoo
Kaur Alasoo
JRJulia Rodrigues
Julia Rodrigues
SMSubhankar Mukhopadhyay
Subhankar Mukhopadhyay
AKAndrew J. Knights
Andrew J. Knights
DGDaniel J. Gaffney
Daniel J. Gaffney

6 March 2022 in medRxiv
Verified
Preprint
Open access
PDF file
MKMitja I. Kurki
Mitja I. Kurki
JKJuha Karjalainen
Juha Karjalainen
PPPriit Palta
Priit Palta
TSTimo P. Sipilä
Timo P. Sipilä
KKKati Kristiansson
Kati Kristiansson
APAarno Palotie
Aarno Palotie
Population isolates such as Finland provide benefits in genetic studies because the allelic spectrum of damaging alleles in any gene is often concentrated on a small number of low-frequency variants (0.1% ≤ minor allele frequency < 5%), which survived the founding bottleneck, as opposed to being distributed over a much larger number of ultra--rare variants. While this advantage is well-- established in Mendelian genetics, its value in common disease genetics has been less explored. FinnGen aims to study the genome and national health register data of 500,000 Finns, already reaching 224,737 genotyped and phenotyped participants. Given the relatively high median age of participants (63 years) and dominance of hospital-based recruitment, FinnGen is enriched for many disease endpoints often underrepresented in population-based studies (e.g., rarer immune-mediated diseases and late onset degenerative and ophthalmologic endpoints). We report here a genome-wide association study (GWAS) of 1,932 clinical endpoints defined from nationwide health registries. We identify genome--wide significant associations at 2,491 independent loci. Among these, finemapping implicates 148 putatively causal coding variants associated with 202 endpoints, 104 with low allele frequency (AF<10%) of which 62 were over two-fold enriched in Finland. We studied a benchmark set of 15 diseases that had previously been investigated in large genome-wide association studies. FinnGen discovery analyses were meta-analysed in Estonian and UK biobanks. We identify 30 novel associations, primarily low-frequency variants strongly enriched, in or specific to, the Finnish population and Uralic language family neighbors in Estonia and Russia. These findings demonstrate the power of bottlenecked populations to find unique entry points into the biology of common diseases through low-frequency, high impact variants. Such high impact variants have a potential to contribute to medical translation including drug discovery.

11 December 2017 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
HCHIPSCI Consortium
HIPSCI Consortium
JSJeremy Schwartzentruber
Jeremy Schwartzentruber
SFStefanie Foskolou
Stefanie Foskolou
HKHelena Kilpinen
Helena Kilpinen
JRJulia Rodrigues
Julia Rodrigues
DGDaniel J. Gaffney
Daniel J. Gaffney

25 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
APAnusri Pampari
Anusri Pampari
ASAnna Shcherbina
Anna Shcherbina
EKEvgeny Z. Kvon
Evgeny Z. Kvon
MKMichael Kosicki
Michael Kosicki
SNSurag Nair
Surag Nair
AKAnshul Kundaje
Anshul Kundaje
Despite extensive mapping of cis-regulatory elements (cREs) across cellular contexts with chromatin accessibility assays, the sequence syntax and genetic variants that regulate transcription factor (TF) binding and chromatin accessibility at context-specific cREs remain elusive. We introduce ChromBPNet, a deep learning DNA sequence model of base-resolution accessibility profiles that detects, learns and deconvolves assay-specific enzyme biases from regulatory sequence determinants of accessibility, enabling robust discovery of compact TF motif lexicons, cooperative motif syntax and precision footprints across assays and sequencing depths. Extensive benchmarks show that ChromBPNet, despite its lightweight design, is competitive with much larger contemporary models at predicting variant effects on chromatin accessibility, pioneer TF binding and reporter activity across assays, cell contexts and ancestry, while providing interpretation of disrupted regulatory syntax. ChromBPNet also helps prioritize and interpret regulatory variants that influence complex traits and rare diseases, thereby providing a powerful lens to decode regulatory DNA and genetic variation.